Cetuximab - CAS 205923-56-4
Catalog number: B0084-173938
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Unspecified
Molecular Weight:
Unspecified
COA:
Inquire
Targets:
EGFR
Purity:
95%
Synonyms:
N-(2-phenylethoxy)-1-pyridin-4-ylmethanimine; MLS002608064; AC1L5VKQ; CHEMBL1736329; MolPort-001-793-950; HMS3092B19
MSDS:
Inquire
Quantity:
Data not available, please inquire.
InChIKey:
KSSSPNXPNSIVQI-UHFFFAOYSA-N
InChI:
InChI=1S/C14H14N2O/c1-2-4-13(5-3-1)8-11-17-16-12-14-6-9-15-10-7-14/h1-7,9-10,12H,8,11H2
Canonical SMILES:
C1=CC=C(C=C1)CCON=CC2=CC=NC=C2
1.Intravenous injection of leconotide, an omega conotoxin: synergistic antihyperalgesic effects with morphine in a rat model of bone cancer pain.
Kolosov A;Aurini L;Williams ED;Cooke I;Goodchild CS Pain Med. 2011 Jun;12(6):923-41. doi: 10.1111/j.1526-4637.2011.01118.x. Epub 2011 May 3.
OBJECTIVE: ;Leconotide (CVID, AM336, CNSB004) is an omega conopeptide similar to ziconotide, which blocks voltage sensitive calcium channels. However, unlike ziconotide, which must be administered intrathecally, leconotide can be given intravenously because it is less toxic. This study investigated the antihyperalgesic potency of leconotide given intravenously alone and in combinations with morphine-administered intraperitoneally, in a rat model of bone cancer pain.;DESIGN: ;Syngeneic rat prostate cancer cells AT3B-1 were injected into one tibia of male Wistar rats. The tumor expanded within the bone causing hyperalgesia to heat applied to the ipsilateral hind paw. Measurements were made of the maximum dose (MD) of morphine and leconotide given alone and in combinations that caused no effect in an open-field activity monitor, rotarod, and blood pressure and heart rate measurements. Paw withdrawal thresholds from noxious heat were measured. Dose response curves for morphine (0.312-5.0 mg/kg intraperitoneal) and leconotide (0.002-200 µg/kg intravenous) given alone were plotted and responses compared with those caused by morphine and leconotide in combinations.;RESULTS: ;Leconotide caused minimal antihyperalgesic effects when administered alone.
2.CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain.
Kolosov A;Goodchild CS;Cooke I Pain Med. 2010 Feb;11(2):262-73. doi: 10.1111/j.1526-4637.2009.00741.x. Epub 2009 Nov 25.
OBJECTIVE: ;Leconotide is an omega-conotoxin that blocks neuronal voltage sensitive calcium channels. This study compared the antihyperalgesic potencies of leconotide and ziconotide given intravenously alone and in combinations with a potassium channel modulator flupirtine, given intraperitoneally, in a rat model of diabetic neuropathic pain.;DESIGN: ;Rats were given streptozotocin (150 mg/kg ip) to induce diabetic neuropathy and hyperalgesia. Experiments were performed on diabetic rats with >or=30% hyperalgesia to noxious heat. Rats were given each conopeptide alone and with flupirtine. Open field activity monitoring and non-invasive blood pressure measurements were used to define the maximum doses and combinations that caused no side effects. Doses in a range up to maximum no side effect doses were tested for antihyperalgesic effects in rats with hyperalgesia.;RESULTS: ;The maximum no side effect dose of leconotide (2 mg/kg intravenously) caused 51.7% reversal of hyperalgesia compared with 0.4% for the highest no side effect dose of ziconotide (0.02 mg/kg; P < 0.001, one-way anova). Leconotide caused dose-related antihyperalgesic effects that were potentiated by coadministration with flupirtine at doses that were ineffective when given alone.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related EGFR Products


PF-06459988
(CAS: 1428774-45-1)

PF-06459988 is a third-generation, irreversible epidermal growth factor receptor (EGFR) inhibitor. It can bind to and inhibit mutant forms of EGFR, including th...

CAS 848942-61-0 AZD-8931

AZD-8931
(CAS: 848942-61-0)

Sapitinib, also known as AZD-8931, is an erbB receptor tyrosine kinase inhibitor with potential antineoplastic activity. AZD8931 binds to and inhibits erbB tyro...

CAS 1508250-71-2 EGF816

EGF816
(CAS: 1508250-71-2)

EGF816, also called as Nazartinib, a covalent mutant-selective EGFR inhibitor and potently inhibits the T790M resistance mutation while sparing wild-type EGFR. ...

CAS 289499-45-2 Canertinib dihydrochloride

Canertinib dihydrochloride
(CAS: 289499-45-2)

Canertinib dihydrochloride is the hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities. Caner...

CAS 133550-41-1 AG 556

AG 556
(CAS: 133550-41-1)

AG 556, a dihydroxyphen derivative, has been found to be a EGFR kinase inhibitor that could probably be effective in the study of myocardial infarct and hemodyn...

CAS 497839-62-0 AEE-788

AEE-788
(CAS: 497839-62-0)

AEE-788 is an orally bioavailable multiple-receptor tyrosine kinase inhibitor. AEE788 inhibits phosphorylation of the tyrosine kinases of epidermal growth facto...

NT113
(CAS: 1398833-56-1)

NT113 is a pan-ERBB inhibitor with high brain penetrance. It can inhibit the growth of glioblastoma xenografts with EGFR amplification. NT113 is active against ...

MTX-211
(CAS: 1952236-05-3)

MTX-211 is a dual inhibitor of EGFR and PI3K, which plays important roles in the progression of KRAS mutant colorectal cancer. MTX-211 has the potential for the...

Chemical Structure

CAS 205923-56-4 Cetuximab

Quick Inquiry

Verification code

Featured Items